June 2, 2021 06:16 PM EDT
R&D

#AS­CO21: No­var­tis gears up for CAR-T fight with Gilead in fol­lic­u­lar lym­phoma — and safe­ty could de­fine the bat­tle

Nicole DeFeudis

Editor

Since win­ning the first CAR-T ap­proval in the US back in 2017, No­var­tis has been hard at work ex­pand­ing the reach of its block­buster can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times